Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Joshua F. Zeidner, MD, Jonathan M. Gerber, MD, Amanda Blackford, Mark Litzow, MD, Matthew C. Foster, MD, Lawrence E. Morris, Jr., MD, Ivana Gojo, MD, Jeffrey E. Lancet, MD, Prithviraj Bose, MD, Raoul Tibes, MD, Stephen A. Strickland, MD, MSCI, Jacqueline M Greer, RN, Michelle Drye, Kevin Meads, Austin Doyle, MD, Richard F Little, MD, MPH, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 47.

https://doi.org/10.1182/blood.V120.21.47.47

Published: 2012

Journal Articles

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Blood (2012) 119 (1): 55–63.

https://doi.org/10.1182/blood-2011-08-370825

Published: 2012

Includes: Supplemental data

Journal Articles

Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Leukemias,

Amer M. Zeidan, MD, Hetty E Carraway, MD, MBA, Hyun Don Yun, MD, Jacqueline M Greer, RN, Judith E. Karp, MD

Blood (2011) 118 (21): 3615.

https://doi.org/10.1182/blood.V118.21.3615.3615

Published: 2011

Journal Articles

Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia

Brian M. Thomas, MD, Scott H. Kaufmann, MD, PhD, Jacqueline M Greer, RN, Steven D. Gore, MD, Keith W. Pratz, MD, B. Douglas Smith, MD, Karen Mackey, RN, Sabine Loechner, MPA, Jo Ann Horowitz, MD, Judith E. Karp, MD

Blood (2011) 118 (21): 1531.

https://doi.org/10.1182/blood.V118.21.1531.1531

Published: 2011

Journal Articles

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

Judith E. Karp, B. Douglas Smith, Linda S. Resar, Jacqueline M. Greer, Amanda Blackford, Ming Zhao, Dwella Moton-Nelson, Katrina Alino, Mark J. Levis, Steven D. Gore, Biju Joseph, Hetty Carraway, Michael A. McDevitt, Lorena Bagain, Karen Mackey, Janet Briel, L. Austin Doyle, John J. Wright, Michelle A. Rudek

Blood (2011) 117 (12): 3302–3310.

https://doi.org/10.1182/blood-2010-09-310862

Published: 2011

Journal Articles

Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML)

Judith E. Karp, MD, John M. Pagel, MD, PhD, B. Douglas Smith, MD, Jacqueline M Greer, RN, D. Michelle Drye, RN, Kelly M. Smith, MD, Kathleen Dorcy, RN, John J Wright, MD, PhD, L. Austin Doyle, MD, PhD, Elizabeth Garrett-Mayer, PhD, Elihu H. Estey, MD

Blood (2010) 116 (21): 186.

https://doi.org/10.1182/blood.V116.21.186.186

Published: 2010

Journal Articles

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

Blood (2009) 113 (20): 4841–4852.

https://doi.org/10.1182/blood-2008-08-172726

Published: 2009

Includes: Supplemental data

Journal Articles

In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Rebecca M. Ricklis, MS, Judith E. Karp, MD, Eric J. Feldman, MD, Suzanne Galkin, BA, Jacqueline M. Greer, RN, Valerie Ironside, CRNP, Kim Mirjafary, Timothy D. Talbot, BA, Lawrence E. Morris, MD, John J. Wright, MD, PhD, Scott H. Kaufmann, MD, PhD

Blood (2007) 110 (11): 914.

https://doi.org/10.1182/blood.V110.11.914.914

Published: 2007

NARROW

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Leukemias,

Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML)

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only